间充质干细胞治疗ALI的研究进展

Research progress of mesenchymal stem cells in the treatment of ALI

急性肺损伤（ALI）是一种临床常见的危重病症,其发展到严重阶段为急性呼吸窘迫综合征（ARDS）,患者发病急,病死率高,目前尚无有效的治疗方法,是亟待解决的医学难题之一.基于许多临床预试验结果证实,间充质干细胞（MSCs）作为ALI的有效治疗策略具有很大的应用前景,目前对MSCs治疗作用的研究从现象逐渐深入到分子机制,并不断取得新成果,临床试验也开始有了突破性的进展.然而,对于MSCs在临床中的具体应用方法和风险,特别是医源性肿瘤形成风险等仍未解决.本文针对近年来在MSCs治疗ALI的作用机制方面取得的突破性进展和临床试验应用过程中存在的主要问题进行综述,以探讨MSCs治疗ALI的可行性和未来努力方向,从而促进ALI的有效治疗.

Acute lung injury （ALI） is one of the most common clinical critical illnesses. Its severe stage is acute respiratory distress syndrome （ARDS）, characterized by rapid onset and high mortality. There is no effective treatment. Based on many preclinical studies, mesenchymal stem cells （MSCs） have great potential as a therapeutic strategy for ALI, clinical trials are underway, and studies on the therapeutic effects of MSCs progressively deep into the molecular mechanism and continue to make new progress. However, the use of MSCs, their specific methods and risks, especially on the risk of iatrogenic tumor formation remains unresolved. In this paper, we reviewed the main problems in the application of MSCs in the treatment of ALI and the main problems in the application of MSCs in order to explore the feasibility and future direction of MSCs in the treatment of ALI.